RxDoctor Payments Data

John Friedline, MD

Family Medicine · El Centro, CANPI 1447311261

Payments from drug & device makers

$4,592in general payments, 2019–2025

Across 279 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$782
  • Johnson & Johnson$778
  • Novo Nordisk$471
  • GSK$385
  • AstraZeneca$349
  • Lilly USA, LLC$267
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,592 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$219,341
Medicare patients
294
Services billed
4,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide152$157,215
OzempicSemaglutide99$125,655
RybelsusSemaglutide80$124,757
JardianceEmpagliflozin71$68,086
TrulicityDulaglutide45$66,635
EliquisApixaban71$66,174
FarxigaDapagliflozin Propanediol52$54,824
LinzessLinaclotide66$52,354
JanuviaSitagliptin Phosphate56$52,258
XifaxanRifaximin16$48,297
XareltoRivaroxaban34$35,817
EntrestoSacubitril/Valsartan32$32,618
KerendiaFinerenone26$24,554
JanumetSitagliptin Phos/Metformin Hcl27$23,123
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$22,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$471$250,412179 claims
Lilly USA, LLCMounjaro, Trulicity$267$223,850197 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$146$87,66794 claims
AstraZenecaFarxiga, Breztri Aerosphere$349$77,70473 claims
MerckJanuvia, Janumet$94$75,38083 claims
PfizerEliquis$16$66,17471 claims
AbbVieLinzess$169$52,35466 claims
Johnson & JohnsonXarelto$778$35,81734 claims
NovartisEntresto$200$32,61832 claims
BayerKerendia$70$24,55426 claims
Astellas Pharma US IncMyrbetriq$34$11,74525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in El Centro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →